Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood- Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

NCT06265220 is registered in ClinicalTrials.gov with Artiva Biotherapeutics, Inc. as lead sponsor.

NCT NCT06265220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06265220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood- Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
Lead sponsor
Artiva Biotherapeutics, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 3, 2024
Completion date
August 31, 2027
Enrollment
51 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

lupus nephritis - who class iii, lupus nephritis - who class iv, refractory systemic lupus erythematosus, sle